(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2018.
20181026-HBP-Press-Release-Announces-Fiscal-2018-Results-FINAL.pdf